⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Thyrocare Technologies Limited (THYROCARE) Q2 FY27 Financial Results: PAT ₹42.7 & Revenue ₹185.2 Cr(3 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance Neutral 📄 PDF
MetricValue
Revenue₹185.2 Cr
Net Profit (PAT)₹42.7
📢 Key Event
Board approves Ernst & Young LLP as internal auditor for FY 2026-27
💡 Investor Takeaway
The appointment ensures continued audit oversight for the upcoming fiscal year.

Thyrocare Technologies announced the appointment of Ernst & Young LLP as its internal auditor for the financial year 2026-27 following board approval on July 23, 2026, alongside the release of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which are available on the company's investor portal.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
📢 Key Event
Thyrocare released investor presentation for Q1 FY27 unaudited financial results
💡 Investor Takeaway
Strong revenue and PAT growth signals healthy execution and scalable franchise model.

Thyrocare reported consolidated revenue of ₹240 crores, up 24% YoY, with PAT rising 34% to ₹51.33 crores in Q1 FY27, driven by strong pathology growth and improved margins.

3 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
MetricValue
Revenue₹240.02 Cr
Net Profit (PAT)₹51.33
📢 Key Event
Thyrocare reported Q1FY27 revenue of ₹240.02 Cr, up 24% YoY, with PAT up 34% to ₹51.33 Cr.
🔄 What Changed
34% YoY growth in consolidated EBITDA to ₹77.27 Cr and 28% YoY increase in test volume to 55.2 million
🔮 What's Next
Phased expansion of specialty test menu underway, focusing on allergy and genomics testing
💡 Investor Takeaway
Strong volume and revenue growth with expanding specialty diagnostics portfolio supports future margin expansion.

Thyrocare Technologies reported consolidated revenue of ₹240.02 Cr in Q1FY27, up 24% YoY, driven by 26% growth in pathology revenue and 28% test volume growth to 55.2 million. Consolidated EBITDA rose 34% to ₹77.27 Cr, and PAT surged 34% to ₹51.33 Cr, reflecting strong operational efficiency and expansion into specialty diagnostics including allergy and genomics testing.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — THYROCARE ✨ Ask AI About This

About Thyrocare Technologies Limited (THYROCARE)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹9,566.63 Cr P/E: 35.2 ROE: 34.3% ROCE: 45.6% Div Yield: 1.16%

View full THYROCARE stock details →

📡 Get AI alerts when THYROCARE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track THYROCARE — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More THYROCARE filings

See all THYROCARE filings →

🔥 Also filed on 23 July 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when THYROCARE files new disclosures

Track THYROCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track THYROCARE — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd